Advertisement

Advertisement

News

IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC

News

ESMO 2021: DESTINY-Breast03 Trial of T-DXd Versus T-DM1 in HER2-Positive Breast Cancer

News

ESMO 2021: 5-Year Outcomes With Nivolumab Plus Ipilimumab in Kidney Cancer

News

AUA 2021: Interim Analysis of Novel Immunotherapy for BCG-Unresponsive Bladder Cancer

News

AUA 2021: KEYNOTE-564 Focuses on Adjuvant Immunotherapy for Renal Cell Carcinoma

Medical Literature

Can Combination of Targeted Therapy and Immunotherapy Improve Surgical Outcomes in Renal Cell Carcinoma?

News

Pembrolizumab Receives Full FDA Approval for Certain Patients With Advanced Urothelial Carcinoma

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Brian I. Rini, MD, on Using Biomarkers to Inform Treatment Decisions in Renal Cell Carcinoma

View More

Advertisement

JNCCN Spotlights

(UPDATE) Pembrolizumab (NSCLC)

(UPDATE) Pertuzumab (Breast Cancer)

(UPDATE) Daratumumab (MM)

View More

More

News

Novel Monoclonal Antibody and Chemotherapy Combination Under Study in Resistant AML

Isatuximab Under Study in Daratumumab-Refractory Multiple Myeloma

Adding Atezolizumab to Chemotherapy for Muscle-Invasive Bladder Cancer

SOHO 2021: Update on BCMA-Directed CAR T-Cell Therapy for Resistant Myeloma

ESMO 2021: Durvalumab-Based Combinations in COAST Trial of Locally Advanced NSCLC

Atezolizumab in Resistant Advanced Urothelial Cancer: Prognostic Significance of Pretreatment Factors

Enfortumab Vedotin-ejfv Under Study in Cisplatin-Ineligible Urothelial Carcinoma

Avelumab in Electrochemotherapy-Resistant Merkel Cell Carcinoma: Case Report

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

High-Rick Relapsing MM: Retreatment With Immunomodulatory Therapy

JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

View More

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.